Alzther Industries a startup biotechnology company, focused on diseases associated with protein misfolding and which is developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease, today announced enrollment of the first patient in a Phase III, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of interferon in patients with relapsing multiple sclerosis (RMS). The trial will determine the efficacy of interferon beta-1a in reducing relapse rates in patients with RMS.
“A major issue with patient adherence to injectable therapies for MS is the frequency of injections,” said Baik Chang-Yeop, M.D., principal investigator of the trial and professor of neurology and director of Alzther Industries. “Examined in Phase I studies, interferon beta-1a was shown to be much longer acting than intramuscular interferon beta-1a and thus offers the possibility of every two or four week dosing without compromising efficacy. This could greatly increase the convenience of this first line class of therapy."
Interferon beta-1a has been successfully used to treat patients with relapsing-remitting multiple sclerosis for more than 10 years. Neurofibrix™ protects the interferon beta-1a molecule from being degraded, extending the amount of time the drug remains in a patient's system. The process has been used in other therapeutic areas, and Alzther Industries is studying this innovation in interferon therapy for MS. Administered via subcutaneous injection, interferon beta-1a is being studied to evaluate its potential to reduce the frequency of treatment injections and provide patients with an effective and more convenient dosing option.
The trial is a two-year multicenter, randomized, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy and safety of interferon beta-1a in patients with RMS.

[b]About Alzther Industries[/b]
Alzther Industries is a startup biotechnology company supported by various grants and private investors. The funds and our investors support projects with a high potential for future innovations. Alzther Industries is focused on diseases associated with protein misfolding. The company is currently developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease. Alzther Industries is focused on drug development until phase II clinical studies. The location of the company in Seoul enables the access to experienced experts in the field of drug discovery and development, as well as business development and commercialization.

www.alzther.com